Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arobase: Maintenance Bevacizumab with Exemestane vs Paclitaxel in Metastatic Breast Cancer
NCT01303679Phase 3Terminated
- Sponsor
- ARCAGY
- Start
- Jun 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exemestane in breast cancer (2 arms), sponsored by ARCAGY. Primary endpoint: Progression-Free Survival at 24 months. Started Jun 2010; status: terminated.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01303679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01303679.